AbbVie

What AbbVie does

AbbVie is a global biopharmaceutical company founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois (NYSE: ABBV). The company discovers, develops, manufactures, and commercializes innovative medicines across six therapeutic areas of focus — immunology, oncology, neuroscience, virology, eye care, and aesthetics — and via its Allergan Aesthetics subsidiary operates one of the world's largest aesthetics businesses (BOTOX, the JUVÉDERM collection, Skinvive, and the newly approved Boey neurotoxin). AbbVie's products reach approximately 74 million patients in 180+ countries through direct enterprise field sales to healthcare professionals, country-specific affiliate distribution, specialty pharmacy and authorized trading partners, and patient assistance channels. The portfolio includes 12 blockbuster products each generating more than $1 billion in 2025 net revenues, anchored by the Skyrizi + Rinvoq immunology franchise ($7.29B in Q1 2026, up 16% YoY) and the legacy Humira franchise in managed biosimilar decline.

The R&D platform spans multiple therapeutic modalities and is organized around five Areas of Innovation: AI & Data Convergence, Genomics, Patient-Focused Drug Development, Precision Medicine, and Therapeutic Modalities & Platforms. AbbVie is advancing next-generation Antibody-Drug Conjugates (ADCs), protein degraders (degradomers), brain shuttles, and oral peptides, with approximately 90 compounds/devices/indications in development and adjusted R&D investment exceeding $85 billion since 2013. The company operates a Genomics Research Center targeting one million whole human genomes and an in-house AI search engine (ARCH) used by researchers, alongside predictive analytics for molecule behavior and generative AI applied to clinical trial design (including synthetic control arm methods). Pipeline is actively replenished through M&A — most recently Cerevel Therapeutics ($8.7B, August 2024) and the pending Apogee Therapeutics acquisition ($10.9B, announced June 2026) — and through 250+ external innovation partnerships.

Revenue is generated primarily through prescription pharmaceutical product sales, with additional streams from aesthetic medicine products (Allergan Aesthetics), and licensing royalties (e.g., MAVIRET glecaprevir discovered by Enanta Pharmaceuticals). AbbVie runs patient access programs (myAbbVie Assist at ≤600% of Federal Poverty Level, serving 99% of uninsured patients who seek assistance; >210K U.S. patients received medicine at no cost in 2025) and co-pay assistance used by >90% of commercially insured U.S. patients. Distribution is supported by DSCSA-compliant serialization (EPCIS, VRS), local affiliates in 180+ countries, and ~57,000 employees in 70+ countries. The company carries a 52-year streak of consecutive dividend increases (Dividend King) and reports Q1 2026 revenue of $15.0 billion (+12.4% YoY), with 2026 adjusted EPS guidance of $14.08–$14.28.

Name

AbbVie

Legal name

AbbVie Inc.

Website

https://abbvie.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

AbbVie is a global biopharmaceutical company developing and commercializing innovative medicines across immunology, oncology, neuroscience, virology, eye care, and aesthetics, serving approximately 74 million patients across 180 countries with a portfolio of 12 blockbuster products.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Immunology therapeutics
• Oncology pharmaceuticals
• Aesthetic medicine products
• Biopharmaceutical research
• Neuroscience drug development

Headquarters

HQ city

North Chicago

HQ country

United States

HQ region

North America

Offices21 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: AbbVie generates the majority of revenue from sales of prescription pharmaceutical products across immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta), neuroscience (Vraylar, Duopa), virology (MAVIRET/Mavyret), and eye care. Q1 2026 immunology franchise (Skyrizi and Rinvoq) generated $7.29 billion in revenue, up 16% year over year. Full-year adjusted EPS guidance raised to $14.08–$14.28 for 2026. 12 blockbuster products with 2025 net revenues greater than $1B.
2. Aesthetic Medicine and Consumer Products: Through Allergan Aesthetics, AbbVie sells aesthetic medicine products including BOTOX Cosmetic, BOTOX Therapeutic, Skinvive by Juvederm, JUVÉDERM fillers, Latisse, CoolSculpting, Boey (trenibotulinumtoxinE), and other medical aesthetics products. Allergan Aesthetics generates revenue across approximately 180 countries and territories. AbbVie/Allergan controls 47% of drug and device AI citation share in the ~$25B U.S. aesthetic medicine market.
3. Licensing Royalties and Partnership Revenue: AbbVie earns royalties from partnerships such as MAVIRET/Mavyret, where glecaprevir was discovered by Enanta Pharmaceuticals and commercialized by AbbVie. The company also participates in licensing agreements with the Medicines Patent Pool for low- and middle-income countries and receives milestone payments from collaborations (e.g., $20M milestone from Sanofi for KT-621 development).

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels10 records

Core offering

AbbVie discovers, develops, manufactures, and commercializes innovative prescription pharmaceuticals and biologics across six therapeutic areas — immunology (Skyrizi, Rinvoq, Humira), oncology (Imbruvica, Venclexta), neuroscience (Vraylar, Duopa, plus acquired Cerevel pipeline), virology (Mavyret for hepatitis C), eye care (Durysta, Ozurdex), and aesthetics (BOTOX Cosmetic, JUVÉDERM, Skinvive, Latisse, Boey through Allergan Aesthetics). The company also supports patients via the myAbbVie Assist and co-pay programs and licenses intellectual property through the Medicines Patent Pool for global access.

Product overview

AbbVie is a global biopharmaceutical company (founded 2013, headquartered in North Chicago, Illinois, with ~57,000 employees in 70+ countries) whose product offering spans six therapeutic areas of focus — Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties — together with an Allergan Aesthetics aesthetics franchise. The core platform consists of a blockbuster immunology franchise (the legacy Humira TNF inhibitor plus the post-LOE growth engines SKYRIZI and RINVOQ), a virology franchise led by MAVIRET/MAVYRET for hepatitis C, an oncology franchise anchored by IMBRUVICA and VENCLEXTO/VENCLYXTO, an aesthetics portfolio (BOTOX/BOTOX Cosmetic, the Juvederm collection, Skinvive by Juvederm, and the newly approved Boey), and an eye care / women's health portfolio (DURYSTA, OZURDEX, LILETTA, NAMZARIC). Acquired pipeline modules include Emraclidine and Tavapadon from the $8.7B Cerevel Therapeutics deal (closed August 2024) for schizophrenia and Parkinson's disease, NX-13 from the Landos Biopharma acquisition (May 2024) for inflammatory bowel disease, and the pending $10.9B acquisition of Apogee Therapeutics (announced June 22, 2026; expected to close Q3 2026) adding lead asset zumilokibart (APG777) and APG273 for atopic dermatitis and asthma. Supporting infrastructure includes a global pharmaceutical supply chain (DSCSA-compliant serialization via EPCIS and VRS), AbbVie Ventures, and 250+ active external innovation partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• Allergan Aesthetics: Aesthetics business unit offering BOTOX Cosmetic, Skinvive by Juvederm, fillers and aesthetic products; completed acquisition in 2020.
• BOTOX Cosmetic
• Skinvive by Juvederm
• Boey
• Skyrizi (risankizumab)
• Humira
• Maviret / Mavyret (glecaprevir/pibrentasvir)

Products and services

• SKYRIZI (risankizumab) IL-23 inhibitor biologic approved for plaque psoriasis (including pediatric patients aged 6+), psoriatic arthritis, and Crohn's disease; one of two principal immunology growth engines replacing Humira post-LOE.
• RINVOQ (upadacitinib) Oral JAK1-selective inhibitor for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, ulcerative colitis, and Crohn's disease; the second principal immunology growth engine replacing Humira post-LOE.
• Humira (adalimumab) TNF inhibitor biologic that was AbbVie's former mega-blockbuster for autoimmune diseases; the franchise faced biosimilar competition beginning in 2023 after AbbVie's patent estate delayed entry seven years past composition-of-matter expiry.
• MAVIRET / MAVYRET (glecaprevir/pibrentasvir) Pan-genotypic hepatitis C regimen (NS3/4A + NS5A inhibitor combination) — the only treatment approved in the EU for both acute and chronic HCV as of June 2026, with 96.2% SVR12 in Phase 3 trials; glecaprevir was discovered by Enanta Pharmaceuticals and commercialized by AbbVie.
• VENCLEXTO / VENCLYXTO (venetoclax) First-in-class BCL-2 inhibitor for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML); nine-year Phase 3 CLL14 data showed 6.4-year median PFS vs 3.2 years with comparator in CLL.
• IMBRUVICA (ibrutinib) First-in-class BTK inhibitor therapy for hematologic cancers; FDA-approved for Waldenström's macroglobulinemia, CLL/SLL, and chronic graft-versus-host-disease; backed by 25+ AbbVie-sponsored clinical trials.
• BOTOX / BOTOX Cosmetic (onabotulinumtoxinA) Allergan Aesthetics flagship neurotoxin for both cosmetic indications (glabellar lines, crow's feet, forehead lines) and therapeutic uses (chronic migraine, spasticity, cervical dystonia, overactive bladder).
• Skinvive by Juvederm Hyaluronic acid injectable FDA-approved (June 16, 2026) to reduce neck wrinkles and improve neck appearance in adults over 21.
• Boey (trenibotulinumtoxinE) New botulinum neurotoxin serotype E approved in Canada (June 23, 2026) for temporary improvement of moderate to severe glabellar lines; offers rapid onset within 8 hours and short duration of approximately 2–3 weeks.
• Allergan Aesthetics portfolio (JUVÉDERM, Latisse, CoolSculpting) Allergan Aesthetics, an AbbVie company, markets the global aesthetics portfolio including the JUVÉDERM collection of hyaluronic acid fillers, Latisse (eyelash growth treatment), and CoolSculpting (fat reduction).
• DURYSTA Sustained-release bimatoprost implant for reduction of intraocular pressure in open-angle glaucoma and ocular hypertension.
• OZURDEX Dexamethasone intravitreal implant for macular edema, retinal vein occlusion, and non-infectious uveitis.
• LILETTA Levonorgestrel-releasing intrauterine system for long-acting contraception (women's health).
• DALVANCE Dalbavancin lipoglycopeptide antibiotic for acute bacterial skin and skin structure infections (ABSSSI).
• TEFLARO Ceftaroline fosamil cephalosporin antibiotic for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
• AVYCAZ Ceftazidime-avibactam cephalosporin/beta-lactamase inhibitor combination for complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and HABP/VABP.
• NAMZARIC Memantine extended-release and donepezil fixed-dose combination for moderate to severe Alzheimer's disease dementia.
• myAbbVie Assist patient assistance program Patient assistance program providing free AbbVie medicine to eligible uninsured/underinsured U.S. patients at or below 600% of the Federal Poverty Level; served 99% of uninsured patients who sought assistance and over 210,000 U.S. patients in 2025.

Quantifiable outcome

• ~74 million patients reached with AbbVie products in 2025
• +9 more outcomes

Segments9 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability10 records

Feature6 records

Partnerships

16 partnerships are on record, tiered flagship, core and minor.

• Apogee TherapeuticsflagshipStrategic or Co-development Partner · 22 June 2026AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash at $135.11 per share (49% premium over prior closing price). Adds lead asset zumilokibart (APG777) — an IL-13 monoclonal antibody for atopic dermatitis in Phase 2 — plus APG273 combination therapy for asthma. Expected to close Q3 2026 and become accretive to adjusted EPS starting 2032. Fairmount Funds Management and Venrock Associates entered voting agreements in support of the deal.
• Cerevel TherapeuticsflagshipStrategic or Co-development Partner · 1 August 2024AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics in August 2024 at $45.00 per share. The acquisition enhances AbbVie's neuroscience pipeline with drug candidates including Emraclidine for schizophrenia and Tavapadon for Parkinson's disease. Expected to be earnings accretive starting in 2030.
• ImmunoGenflagshipStrategic or Co-development Partner · 27 June 2024AbbVie completed the $10.1 billion acquisition of ImmunoGen in 2024 to expand its oncology ADC pipeline. Largest acquisition referenced as preceding the Apogee deal.
• Landos BiopharmacoreStrategic or Co-development Partner · 23 May 2024AbbVie completed acquisition of Landos Biopharma for $137.5 million in cash (March 2024 announcement, completed May 23, 2024) at $20.42 per share plus contingent value rights of up to $11.14 per share based on clinical milestones. Adds Landos' investigational asset NX-13, in Phase 2 trials for ulcerative colitis in the U.S. and Europe, to AbbVie's pipeline.
• Allergan (Allergan Aesthetics)flagshipStrategic or Co-development Partner · 8 May 2020On May 8, 2020, AbbVie completed its acquisition of Allergan, which is now part of AbbVie. Allergan Aesthetics is now an AbbVie company selling BOTOX, JUVÉDERM, Skinvive, LATISSE, Boey, and other aesthetic products. AbbVie/Allergan controls 47% of drug/device AI citation share in the U.S. aesthetic medicine market.
• Enanta PharmaceuticalscoreStrategic or Co-development PartnerGlecaprevir, one of the two active ingredients in AbbVie's MAVIRET/Mavyret (glecaprevir/pibrentasvir), was discovered by Enanta Pharmaceuticals and is being developed and commercialized by AbbVie under the MAVYRET/MAVIRET brand names. Enanta receives ongoing royalties from AbbVie's commercialization. The EC approved MAVIRET for acute HCV in adults and children 3+ in June 2026 based on Phase 3 data showing 96.2% SVR12.
• REGENXBIOcoreStrategic or Co-development PartnerAbbVie has a collaboration with REGENXBIO on ABBV-RGX-314 for wet AMD, with a potential $100 million milestone tied to Phase 3 data expected in Q4 2026.
• Chicago CubsminorGTM or Marketing PartnerAbbVie maintains a brand partnership with the Chicago Cubs for awareness and consumer engagement.
• Major League BaseballminorGTM or Marketing PartnerAbbVie maintains a brand partnership with Major League Baseball for awareness and consumer engagement.
• CommunityHealth (Chicago)coreStrategic or Co-development PartnerThe AbbVie Foundation and CommunityHealth expand access to essential medical services through microsite clinics bringing free health care to Chicago's underserved communities, including the southwest side.
• St. Jude Children's Research HospitalcoreStrategic or Co-development PartnerWith AbbVie's $50 million donation, St. Jude opened a new home-like environment where childhood cancer patient families can relax, recover and connect.
• AMPATH (Kenya)minorImplementation/ SI/ Consulting PartnerAMPATH and the AbbVie Foundation partner to empower expectant mothers in Kenya.
• Neal Math and Science Academy (North Chicago)minorStrategic or Co-development PartnerBuilt with AbbVie's $40 million donation, the new Neal Math and Science Academy in North Chicago reflects the talent and potential of its students.
• Medicines Patent Pool (MPP)coreStrategic or Co-development PartnerAbbVie participates in licensing agreements with the Medicines Patent Pool to increase access to critical medicines for patients in low- and middle-income countries, with global medicine donation programs for patients with no means of access.
• U.S. Chamber of CommerceminorOthersThe U.S. Chamber of Commerce is the largest trade association lobbying at the federal level to which AbbVie belongs. AbbVie provides $25,000 or more in annual membership dues.
• Paragon Therapeutics (related to Apogee, Spyre, Oruka)minorStrategic or Co-development PartnerParagon Therapeutics is the biotech spinout parent of Apogee Therapeutics (which AbbVie is acquiring). Common origins between Apogee and Oruka Therapeutics (which completed a $700.4M public offering). Spyre Therapeutics also part of Paragon ecosystem — its rally was fueled by AbbVie's Apogee acquisition news.

Scale indicators21 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novartis: Direct competitor in immunology (Cosentyx overlaps Skyrizi), oncology (Kisqali competes with Imbruvica/Venclexta), and neuroscience. Similar post-spinoff (2013-era) capital structure and M&A-driven growth model.
• Pfizer: Global biopharmaceutical company with overlapping therapeutic areas including immunology, oncology, neuroscience, and aesthetics. Direct competitor to AbbVie in oncology, vaccines, and primary care/specialty pharmaceuticals with similar global field-sales distribution model.
• Merck & Co. Direct competitor in oncology (Keytruda is the dominant immuno-oncology agent competing with Imbruvica/Venclexta) and operates a comparable large-molecule/small-molecule pipeline. Both companies are patent-cliff-exposed and pursuing pipeline replenishment through M&A.
• Bristol-Myers Squibb: Direct competitor in immunology, oncology, and hematology. Competes with Imbruvica in CLL (via its own BTK and BCL-2 assets) and faces the same post-Humira biosimilar/patent-cliff dynamics; heavy acquirer (Celgene, Karuna, RayzeBio) like AbbVie.
• Eli Lilly: Direct competitor in immunology (Taltz/Olumiant overlap with Skyrizi/Rinvoq), oncology, neuroscience, and increasingly aesthetics. Same R&D-heavy, large-cap biopharma model with global field-sales GTM.
• Amgen: Direct competitor in immunology (Enbrel, Otezla, Tezspire), oncology (Blincyto, Lumakras), and neuroscience. Comparable biologics-heavy manufacturing footprint and heavy reliance on enterprise sales to rheumatologists, dermatologists, and oncologists.
• Roche: Global biopharma peer with overlapping oncology, immunology, and neuroscience franchises plus a diagnostics arm. Comparable in R&D intensity, biologics manufacturing, and pipeline replenishment strategy.
• Sanofi: Direct competitor in immunology (Dupixent competes with Rinvoq/Skyrizi in atopic dermatitis — and now with incoming zumilokibart) and operates a comparable European-anchored specialty care franchise with global field-sales reach.
• GSK: Global biopharma peer with overlapping HIV/viral (ViiV), oncology (Jemperli), and immunology pipelines. Similar size, geographic mix, and reliance on blockbuster franchises facing LOE pressure.

Broad incumbents

• Johnson & Johnson (Innovative Medicine): Broad incumbent across immunology (Stelara/Tremfya overlapping with Humira/Skyrizi/Rinvoq), oncology, neuroscience, and a sizable MedTech aesthetics franchise (Mentor, SkinTyte). Larger, more diversified peer with overlapping but broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/abbvie
• YouTubeyoutube.com/user/AbbVie
• Facebookfacebook.com/AbbVieGlobal
• LinkedInlinkedin.com/company/abbvie
• Instagraminstagram.com/abbvie
• TikToktiktok.com/@abbvie

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles26 records

Subsidiaries4 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A16 records

Investments89 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AbbVie